Ronald W. Busuttil, MD, PhD: William P. Longmire, JR, Chair of Surgery, Chief of Liver and Pancreas Transplantation, Director, UCLA-Dumont Transplant & Liver Cancer Center

Ronald W. Busuttil

doi:10.1097/TP.0000000000002077

Ronald W. Busuttil, MD, PhD: William P. Longmire, JR, Chair of Surgery, Chief of Liver and Pancreas Transplantation, Director, UCLA-Dumont Transplant & Liver Cancer Center

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	713-715
Number of pages	3
Journal	Transplantation
Volume	102
Issue number	5
DOIs	https://doi.org/10.1097/TP.0000000000002077
State	Published - May 1 2018

ASJC Scopus subject areas

Transplantation

Access to Document

10.1097/TP.0000000000002077

Cite this

@article{28f3fa342e8f4a18ba350a7da65dd0a1,

title = "Ronald W. Busuttil, MD, PhD: William P. Longmire, JR, Chair of Surgery, Chief of Liver and Pancreas Transplantation, Director, UCLA-Dumont Transplant & Liver Cancer Center",

author = "Busuttil, {Ronald W.}",

note = "Funding Information: been recently awarded a 5-year Program Project Grant from the NIH. As there are less than 10 program project grants in the country funded by the NIH that are related to organ transplantation, this is quite an achievement. The focus of the research on liver ischemia reperfusion injury (IRI) is both basic and translational since IRI contributes to poor graft function after transplantation. Minimizing the adverse effects of IRI could increase the number of patients that may successfully undergo liver transplantation. Our research has involved studying the platelet leukocyte endothelial cell interactions which play a central role in IRI. We were the first group to document that inhibition of P-Selectin activation by blocking P-Selectin glycoprotein ligand-1 was highly successful in increasing survival in marginal liver grafts after transplantation. I have been the principal investigator of these studies since they were initiated in the mid-1990s and currently these have been expanded to the clinical arena with Phase II clinical trials utilizing P-Selectin/ PSGL-1 blockade in both kidney and liver transplantation. In 2012, I was the lead author of a randomized placebo controlled phase II clinical trial comparing placebo versus selectin blockade in a series of 47 patients undergoing liver transplantation. Selectin blockade proved to be nontoxic and improved graft survival, liver function tests and biomarkers of inhibition of IRI. This study is the stimulus for a multicenter trial investigating selectin blockade as a mechanism to improve liver graft function and has applicability to other organ transplants.",

year = "2018",

month = may,

day = "1",

doi = "10.1097/TP.0000000000002077",

language = "English (US)",

volume = "102",

pages = "713--715",

journal = "Transplantation",

issn = "0041-1337",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Ronald W. Busuttil, MD, PhD

T2 - William P. Longmire, JR, Chair of Surgery, Chief of Liver and Pancreas Transplantation, Director, UCLA-Dumont Transplant & Liver Cancer Center

AU - Busuttil, Ronald W.

N1 - Funding Information: been recently awarded a 5-year Program Project Grant from the NIH. As there are less than 10 program project grants in the country funded by the NIH that are related to organ transplantation, this is quite an achievement. The focus of the research on liver ischemia reperfusion injury (IRI) is both basic and translational since IRI contributes to poor graft function after transplantation. Minimizing the adverse effects of IRI could increase the number of patients that may successfully undergo liver transplantation. Our research has involved studying the platelet leukocyte endothelial cell interactions which play a central role in IRI. We were the first group to document that inhibition of P-Selectin activation by blocking P-Selectin glycoprotein ligand-1 was highly successful in increasing survival in marginal liver grafts after transplantation. I have been the principal investigator of these studies since they were initiated in the mid-1990s and currently these have been expanded to the clinical arena with Phase II clinical trials utilizing P-Selectin/ PSGL-1 blockade in both kidney and liver transplantation. In 2012, I was the lead author of a randomized placebo controlled phase II clinical trial comparing placebo versus selectin blockade in a series of 47 patients undergoing liver transplantation. Selectin blockade proved to be nontoxic and improved graft survival, liver function tests and biomarkers of inhibition of IRI. This study is the stimulus for a multicenter trial investigating selectin blockade as a mechanism to improve liver graft function and has applicability to other organ transplants.

PY - 2018/5/1

Y1 - 2018/5/1

UR - http://www.scopus.com/inward/record.url?scp=85059237008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059237008&partnerID=8YFLogxK

U2 - 10.1097/TP.0000000000002077

DO - 10.1097/TP.0000000000002077

M3 - Comment/debate

C2 - 29702537

AN - SCOPUS:85059237008

SN - 0041-1337

VL - 102

SP - 713

EP - 715

JO - Transplantation

JF - Transplantation

IS - 5

ER -

Ronald W. Busuttil, MD, PhD: William P. Longmire, JR, Chair of Surgery, Chief of Liver and Pancreas Transplantation, Director, UCLA-Dumont Transplant & Liver Cancer Center

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this